CarisolvTM approved for sale in the USA

FDA, the American drugs licensing authority, has given MediTeam the go ahead for the marketing of CarisolvTM in the USA. MediTeam is planning to launch CarisolvTM in the USA in 2002.

The US market is the world's largest single market with around 140,000 dentists and almost 150 million cases of dental caries being treated a year.

CarisolvTM is a gentle method of removing caries, which minimises the use of drill and anaesthetic, but above all preserves as much of the healthy tooth as possible.

"Obviously this is an important step for Carisolv", says Claes Holmberg, CEO of MediTeam. "The USA is a major market which we must respect. Carisolv will be introduced gradually, starting with universities and opinion-formers. We have already begun contacting American universities to allow them to test the method and start trials".

MediTeam has contacts with several American companies, which have expressed an interest in marketing CarisolvTM in the USA. FDA approval will strengthen MediTeam's negotiating position. The experience gained in Europe will be very important when it comes to choosing American cooperation partners.

For further information, please contact: *Annette Ravenshorst* Vice President Corporate Communications Phone: +46 31-336 91 21 Mobile: +46 709-72 62 86 annette.ravenshorst@mediteam.com

Claes Holmberg President and CEO

Mobile: +46 708-25 45 47 claes.holmberg@mediteam.com

MediTeam is a Swedish research-oriented dental company that markets new methods world wide based on odontological research. It is currently marketing two products; CarisolvTM—a tissuepreserving method for the removal of caries, and OsstellTM—a unique instrument to measure the clinical performance of dental implants.

www.mediteam.com MediTeam Dental AB (publ). Göteborgsvägen 74. SE-433 63 Sävedalen. Sweden. Phone: +46-31 336 91 00. Fax: +46-31 336 91 91.